rofecoxib has been researched along with Gastric Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Czekaj, R | 1 |
| Majka, J | 1 |
| Magierowska, K | 1 |
| Sliwowski, Z | 1 |
| Magierowski, M | 1 |
| Pajdo, R | 1 |
| Ptak-Belowska, A | 1 |
| Surmiak, M | 1 |
| Kwiecien, S | 1 |
| Brzozowski, T | 1 |
| Nishio, H | 1 |
| Terashima, S | 1 |
| Nakashima, M | 1 |
| Aihara, E | 1 |
| Takeuchi, K | 1 |
| Houben, JJ | 1 |
| Liem, B | 1 |
3 other studies available for rofecoxib and Gastric Diseases
| Article | Year |
|---|---|
Mechanisms of curcumin-induced gastroprotection against ethanol-induced gastric mucosal lesions.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcitonin Gene-Related Peptide; Capsaicin; CDX2 T | 2018 |
Involvement of prostaglandin E receptor EP3 subtype and prostacyclin IP receptor in decreased acid response in damaged stomach.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Bridged Bicyclo Compounds; Caproates; Cyclooxygenase 1; Cyclo | 2007 |
[Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Clinical Trials as Topic; Confounding | 1999 |